Aripiprazole: The evidence of its therapeutic impact in schizophrenia

Core Evidence

Volumn 1, Issue 4, 2006, Pages 251-264

  Winlow, William ^a   Profit, Louise ^a   Chrisp, Paul ^a  

^a Core Medical Publishing ^*  (United Kingdom)

Author keywords

Aripiprazole; Clinical impact; Evidence; Schizophrenia; Treatment

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; OLANZAPINE; PERPHENAZINE; PROLACTIN; RISPERIDONE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; AGITATION; ANXIETY; BLURRED VISION; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HEADACHE; HUMAN; HYPERLIPIDEMIA; HYPOTENSION; INSOMNIA; META ANALYSIS; METABOLIC DISORDER; NAUSEA; PATHOPHYSIOLOGY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRACTICE GUIDELINE; PREVALENCE; PROLACTIN BLOOD LEVEL; PSYCHOSIS; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; TREATMENT OUTCOME; VOMITING; WEIGHT GAIN; XEROSTOMIA;

EID: 33749027752     PISSN: 15551741     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Anon. New drug evaluation: aripiprazole. Newcastle-upon-Tyne: Regional Drug and Therapeutics Centre; July 2004a. Available at: http://www.nyrdtc.nhs. uk/docs/nde/NDE_62_aripiprazole.pdf (accessed October 21, 2005).
2. Anon. Aripiprazole (Abilify®) for the treatment of schizophrenia. Staffordshire: Midland Therapeutic Review & Advisory Committee; Oct 2004b. Available at: http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/verdicts/A/ aripiprazole.pdf (accessed October 21, 2005).
3. Anon. Abilify US Prescribing Information. Available at: www.abilify.com (accessed October 21, 2005).
4. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302:381-389.
5. Carrigan G, Cislo P, Ray S, et al. Risk of rehospitalization in antipsychotic-treated patients. Abstract presented at: 158th Annual Meeting of the American Psychiatric Association; May 21-26, 2005; Atlanta, GA. Abstract NR178.
6. Carson WH, Archibald DG Manos G, et al. Short-term efficacy of aripiprazole on depression and anxiety in schizophrenia. Abstract presented at: 156th Annual Meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, CA. Abstract NR549.
7. Carson W, Marcus R, Jody D, et al. The effectiveness of switch to aripiprazole stratified by prior antipsychotic. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.
8. Casey DE, Carson WH, Saha AR. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology. 2003;166:391-399.
9. Chapman V. New medicines profile: aripiprazole. Leicester: UK Medicines Information Service; 2004. Available at: http://www.ukmi.nhs.uk/NewMaterial/ html/docs/AripiprazoleNMP0604.pdf (accessed October 21, 2005).
10. Clark R. Disease overview - schizophrenia. Drugs in Context. 2005;1:92-100.
11. Cooper-Casey K, Mesen-Fairnardi A, Galke-Rollins B, et al. Suggestive linkage of schizophrenia to 5p13 in Costa Rica. Mol Psychiatry. 2005;10:651-656.
12. El-Sayeh HG, Morganti C. Aripiprazole for schizophrenia (review). Cochrane Database Syst Rev. 2004;(2):CD004578.pub2.
13. Falkai P, Wobrock T, Liebermann J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia. Part 1: acute treatment of schizophrenia. World Journal Biol Psych. 2005;6:132-191.
14. Folsom DP, Jeste DV. Schizophrenia in homeless persons: a systematic review of the literature. Acta Pyschiatr Scand. 2002;105:404-413.
15. Folsom DP, Hawthorne W, Lindamer L, et al. Prevalence and risk factors for homelessness and utilization of mental health services among 10,340 patients with serious mental illness in a large public mental health system. Am J Psychiatry. 2005;162:370-376.
16. Gilmer TP, Folsom DP, Hawthorne W, et al. Assisted living and use of health services among Medicaid beneficiaries with schizophrenia. J Ment Health Policy Econ. 2003;6:59-65.
17. 1A receptor. Eur J Pharmacol. 2002;441:137-140.
18. Kandel ER. Disorders of thought and volition: schizophrenia. In: Kandel ER, Schwartz JA, Jessell TM, editors. Principles of neural science. 4th ed. New York: McGraw-Hill; 2000. pp. 1188-1208.
19. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002;63:763-771.
20. Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Neuropsychopharmacology. 2003;6:325-337.
21. Kelly DL, Conley RR. Sexuality and schizophrenia. Schizophrenia Bull. 2004;30:767-779.
22. Kemmler G, Hummer M, Widschwendter C, Fleischhacker W. Dropout rates in placebo-controlled and active-controlled trials of antipsychotic drugs: a meta-analysis. Arch Gen Psychiatry. 2005;62:1305-1312.
23. Launer M. Partial dopamine agonists in schizophrenia. Hospital Med. 2005;66:300-303.
24. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(Suppl.):1-56.
25. Lewis DA, Lieberman JA. Catching up on schizophrenia: natural history and neurobiology. Neuron. 2000;28:325-334.
26. Liberty IF, Todder D, Umansky R, Harman-Boehm I. Atypical antipsychotics and diabetes mellitus: an association. IMAJ. 2004;6:276-279.
27. Lieberman JA. Dopamine partial agonists. A new class of antipsychotic. CNS Drugs. 2004;18:251-267.
28. Lieberman JA, Mailman RB, Duncan G, et al. Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol Psychiatry. 1998;44:1099-1117.
29. Lieberman JA, Perkins D, Belger A, et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry. 2001;50:884-897.
30. Lien L. Economic factors influencing the implementation of community care for severely ill schizophrenic patients. World Hosp Health Serv. 2005;41:21-24.
31. Lindamer AL, Bailey A, Hawthorne W, et al. Gender differences in characteristics and service use of public mental health patients with schizophrenia. Psychiatr Serv. 2003;54:1407-1409.
32. Lowyck B, De Hert M, Peeters E, et al. A study of the family burden of 150 family members of schizophrenic patients. Eur Psychiatry. 2004;19:395-401.
33. Lublin H, Eberhard J, Levander S. Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation of antipsychotics. Int Clin Psychopharmacol. 2005;20:183-198.
34. Madhusoodanan S, Brenner R, Gupta S, et al. Clinical experience with aripiprazole treatment in ten elderly patients with schizophrenia or schizoaffective disorder: retrospective case studies. CNS Spectr. 2004;9:862-867.
35. Mallikaarjun S, Salazar DE, Braner SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol. 2004;44:179-187.
36. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophrenia Res. 2003;61:123-136.
37. McQuade RD, Stock E Marcus R, et al. A comparison with weight change during treatment with olanzapine or aripiprazole. J Clin Psychiatry. 2004;65(Suppl.18):47-56.
38. Mortimer A. Antipsychotic treatment in schizophrenia: atypical options and NICE guidelines. Eur Psychiatry. 2003;18:209-219.
39. Newcomer JW. Metabolic risk of antipsychotic treatment. Clin Ther. 2004;2:1936-1946.
40. NICE (National Institute for Health and Clinical Excellence). Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Technology appraisal guidance No. 43. London: NICE; 2002a. Available at: http://www.nice.org.uk (accessed October 21, 2005).
41. NICE (National Institute for Health and Clinical Excellence). Schizophrenia. Core interventions in the treatment and management of schizophrenia in primary and secondary care. Clinical guideline 1. London: NICE; 2002b. Available at: http://www.nice.org.uk (accessed October 21, 2005).
42. Ohlsen RI, Pilowsky LS. The place of partial agonism in psychiatry: recent developments. J Psychopharmacol. 2005;19:408-413.
43. Olfson M, Corey-Lisle PK, Marcus S, et al. Hyperlipidemia following treatment with antipsychotic medications. Abstract presented at: 158th Annual Meeting of the American Psychiatric Association; May 21-26, 2005a. Abstract NR175.
44. Olfson M, Carrigan G, Corey-Lisle PK, Cislo P, Ray S. Discontinuation rates among treated schizophrenia patients in managed care. Abstract presented at: 158th Annual Meeting of the American Psychiatric Association; May 21-26, 2005b. Abstract NR174.
45. Owen MJ, O'Donovan MC, Harrison PJ. Schizophrenia: a genetic disorder of the synapse. BMJ. 2005;330:158-159.
46. Pigott TA, Carson WH, Saha AR. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry. 2003;64:1048-1056.
47. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risiperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2003;60:681-690.
48. Ramaswamy S, Vijay D, William M, et al. Aripiprazole possibly worsens psychosis. Int Clin Psychopharmacol. 2004;19:45-48.
49. RANZCP (Royal Australian and New Zealand College of Psychiatrists). Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust NZ J Psychiatry. 2005;39:1-30.
50. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia. JAMA. 2005;294:1934-1943.
51. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacol. 2003;28:1400-1411.
52. Tandon R, Marcus RN, Stock EG, et al. A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). Schizophrenia Res. 2006;84:77-89.
53. Travis MJ, Burns T, Dursun S, et al. Aripiprazole in schizophrenia: consensus guidelines. Int J Clin Pract. 2005;59:485-495.
54. van Rijn S, Aleman A, Swaab H, Kahn RS. Neurobiology of emotion and high risk for schizophrenia: role of the amygdala and the X-chromosome. Neurosci Biobehav Rev. 2005;29:385-397.
55. Vantalon V, Briard-Luginbuhl V, Mouren MC. Fragile X syndrome and very early onset schizophrenia: a female case study (in French). Arch Pediatr. 2005;12:176-179.
56. Volavka J, Czobor P, Citrome L, et al. Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies. J Clin Psychiatry. 2005;66:1362-1366.